OpenAI's GPT-5 Conducts 36,000 Robotic Experiments, Cuts Protein Creation Costs by 40%

OpenAI's GPT-5 Achieves Autonomous Biological Experiments OpenAI’s GPT-5 autonomously operated 36,000 experiments via a robotic lab.

The model cut the cost of creating a target protein by 40%. AI can now design and run biological experiments. Semafor reported these developments as part of advancements in AI-driven biology. These experiments showcase GPT-5's ability to manage large-scale autonomous lab operations, though experts warn this could lower barriers to biological engineering for unintended uses.

This includes both the design phase and execution through robotic systems.

Scientist Warns of Regulatory Gaps and Bioterrorism Risks A leading scientist warned that AI is racing ahead of regulatory systems and raising the risk of bioterrorism.

Stephen Turner wrote in The Conversation that AI is making biological engineering more accessible and lowering the barriers to use. These statements highlight concerns over the pace of AI integration in biological fields. Semafor reported the leading scientist's warning in the context of recent AI capabilities.

Turner's article in The Conversation addresses how AI tools democratize access to biological engineering. The lowered barriers could enable broader participation in such activities.

Attack on Sam Altman's Home Occurs Amid AI Developments Sam Altman’s home was targeted in a second attack in two days this weekend.

The incident follows a prior attack on the same location. No further details on the attacks were provided. Semafor reported the attacks as occurring over the weekend prior to April 13, 2026. The timing coincides with reports on OpenAI's advancements, though no direct connection was stated.

Altman, associated with OpenAI, has been involved in the company's AI projects.

Broader Context of AI in Biology AI's ability to design and run biological experiments represents a shift in research methodologies.

While GPT-5's handling of 36,000 experiments and 40% cost reduction highlight efficiency in biotechnology, they also amplify debates over regulatory preparedness and safety risks.